Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic

prnewswire.com
ABBV Mentioned as a multinational pharmaceutical company where Dr. Sharma serves as a scientific advisor and speaker in obesity medicine, indicating potential future collaboration or interest in their field. AZN Mentioned as a multinational pharmaceutical company where Dr. Sharma serves as a scientific advisor and speaker in obesity medicine, indicating potential future collaboration or interest in their field. BMY Mentioned as a multinational pharmaceutical company where Dr. Sharma serves as a scientific advisor and speaker in obesity medicine, indicating potential future collaboration or interest in their field. LLY Mentioned as a multinational pharmaceutical company where Dr. Sharma serves as a scientific advisor and speaker in obesity medicine, indicating potential future collaboration or interest in their field. NVO Mentioned as a multinational pharmaceutical company where Dr. Sharma serves as a scientific advisor and speaker in obesity medicine, indicating potential future collaboration or interest in their field.

Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and visceral fat in animal studies. The presentation also marked the first disclosure at an international congress of CBL-514's potential to improve liver metabolic indicators.

NEW TAIPEI CITY, May 19, 2026 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919), a clinical-stage biopharmaceutical company advancing innovative small-molecule therapies in aesthetic medicine, metabolic diseases, and other unmet medical needs, announced that preclinical data on its first-in-class large-area localized fat reduction drug candidate, CBL-514, in combination with GLP-1R-based weight-loss therapies, were presented in an oral presentation on May 14 at the 33rd European Congress on Obesity (ECO 2026), held in Istanbul, Türkiye. The presentation was delivered by Dr. Arya M. Sharma, MD, a scientific advisor to Caliway and an internationally recognized authority in obesity medicine. Dr. Sharma shared with global experts in obesity and metabolism the potential scientific value of CBL-514 as it expands from its core application in aesthetic localized fat reduction into weight management and metabolic benefits.

ECO is one of the most influential international congresses in the field of obesity and metabolic medicine, bringing together more than 4,000 experts from over 100 countries across obesity medicine, metabolic diseases, and weight management to share the latest trends and advances in new drug development. Dr. Sharma is a pioneer in recognizing obesity as a chronic disease and has also been invited to serve as a scientific advisor and speaker in obesity medicine for multiple multinational pharmaceutical companies, including AbbVie, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.

The oral presentation attracted strong attendance, with more than 300 participants, including representatives from multinational pharmaceutical companies, clinicians, academic experts, and industry professionals, further enhancing the visibility of CBL-514 in the international obesity and metabolic medicine fields.

The presentation covered animal study results of CBL-514 in combination with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide. The results showed that CBL-514, when combined with GLP-1R-based weight-loss therapies, demonstrated four complementary and synergistic potentials in animal studies:

Laura Chung, Vice President of Caliway, stated, "We are honored to have Dr. Sharma, an internationally influential authority in obesity medicine, present the animal study data of CBL-514 in combination with GLP-1R-based weight-loss therapies to global experts in obesity and metabolism at ECO 2026. The oral presentation attracted strong participation, with more than 300 attendees, including representatives from multinational pharmaceutical companies, clinicians, academic experts, and industry professionals. This helped enhance the visibility of CBL-514 in the international obesity and metabolic medicine fields and deepen engagement with key potential partners."

Ms. Chung further stated, "As GLP-1R-based therapies rapidly reshape the global weight-loss market, after these therapies successfully help patients lose weight, the next focus of the market is how to help patients become 'healthier and better-contoured after weight loss.' Therefore, next-generation therapies will increasingly focus on improving weight-loss durability, reducing more fat, and improving metabolic health at the same time. This is a key challenge the global industry is actively seeking to address, and it is also where CBL-514 holds one of its most valuable differentiated advantages. The active Q&A following Dr. Sharma's presentation, as well as further discussions with multiple international obesity industry representatives after the session, show that while the industry continues to follow the clinical development of CBL-514 in the aesthetic localized fat reduction market, there is also growing interest in its potential future applications in obesity and metabolic health."

In addition to the ECO 2026 oral presentation, preclinical data on CBL-514 in combination with GLP-1R-based therapies have also been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions in June, which will further expand the international representation of CBL-514 in the global diabetes, obesity, and metabolic medicine fields.

Caliway will continue to deepen its research on CBL-514 in combination with GLP-1R-based therapies and advance human clinical studies this year, while continuing to strengthen the global clinical development strategy and international licensing strategy for CBL-514.

About CBL-514

CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world's first injectable lipolysis drug that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas with no systemic safety risks identified and good tolerability.

To date, 10 clinical trials with a total of 544 subjects have been completed with all efficacy and safety endpoints met.

CBL-514 is being developed across multiple indications, including reduction of subcutaneous fat (non-surgical localized fat reduction) and moderate-to-severe cellulite. CBL-514D, the same active pharmaceutical ingredients (APIs) but under different formulation, is being studied for additional indications such as Dercum's disease and more.

About Caliway Biopharmaceuticals

Caliway Biopharmaceuticals (Caliway) is a clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the Taiwan Exchange (TWSE-6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and other diseases. For more information, please visit: https://www.caliwaybiopharma.com/en/

Media Contact

[email protected]

Disclaimer

This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.

SOURCE Caliway Biopharmaceuticals